Mitsubishi Tanabe Pharma America (MTPA) has enrolled a first patient in a Phase 3 clinical trial of an oral suspension formulation of edaravone in treating amyotrophic lateral sclerosis (ALS). An intravenous form of edaravone (given directly into the bloodstream), developed by Mitsubishi Tanabe Pharma and sold under the brand…
News
A dissolving oral film form of riluzole, called Exservan and able to be taken by amyotrophic lateral sclerosis (ALS) patients without a need for water, has been approved by the U.S. Food and Drug Administration (FDA). Riluzole was the first ALS treatment, approved by the FDA over two decades…
NurOwn showed a good safety profile, as well as potential efficacy in a Phase 2 clinical trial that included people with rapidly progressing amyotrophic lateral sclerosis (ALS). Trial results, which have been previously reported, have now been published in the journal Neurology in a paper titled, “…
A $106 million Weill Family Foundation initiative will bring together interdisciplinary researchers and clinicians at three West Coast universities in hopes of finding new treatments for brain and nervous system disorders such as amyotrophic lateral sclerosis (ALS). The University of California, Berkeley (Berkeley), the University…
Anelixis Therapeutics has completed its Phase 1 clinical trial testing AT-1501, an investigational antibody, in healthy volunteers and eight amyotrophic lateral sclerosis (ALS) patients. The company also announced it has secured the funds to proceed to a Phase 2 clinical trial of AT-1501. The results of the Phase…
Kadimastem plans to submit an amendment to the protocol of its ongoing Phase 1/2a trial in Israel assessing the use of AstroRx, an “off-the-shelf” stem cell therapy, for the treatment of amyotrophic lateral sclerosis (ALS). The company wants to change the planned dosage in one of the…
The ALS Association Golden West Chapter has honored Mitsubishi Tanabe Pharma America (MTPA) with its Essey Commitment to Cures award for advancing research and trials into treatments for amyotrophic lateral sclerosis (ALS) and other efforts. The presentation took place Nov. 15 in San Francisco at the 2019 Champions…
Amyotrophic lateral sclerosis (ALS) is highly prevalent among young U.S. war veterans deployed post-9/11, particularly Air Force personnel, tactical operation officers, and health care workers, a recent study suggests. The findings suggest that there is an early onset of ALS among deployed military service members, the researchers said. Titled…
Aquestive Therapeutics has granted a development and commercialization license to Zambon Pharma for its investigational oral film formulation of riluzole as a treatment for amyotrophic lateral sclerosis (ALS) in the European Union (EU). Under the terms of the agreement, Zambon will be…
Small molecule inhibitors that block the activity of SARM1 — an enzyme that plays a key role in nerve cell degeneration — prevent the degeneration of axons in mice and cellular models of disease, a preclinical study has found. These findings may be the first steps towards the development…
Recent Posts
- ALS nerve damage can occur without TDP-43 protein clumps: Study
- Dealing with loss, both big and small, in life with ALS
- Scientists use fat-based ‘bubbles’ to sneak ALS treatment into the brain
- Guest Voice: ALS hasn’t stopped this go-to guy from showing up as ‘Dad’
- HEALEY ALS platform trial launches new arm testing oral therapy NUZ-001